ClinicalTrials.gov
ClinicalTrials.gov Menu

High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00885703
Recruitment Status : Completed
First Posted : April 22, 2009
Results First Posted : March 12, 2018
Last Update Posted : March 12, 2018
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

April 20, 2009
April 22, 2009
January 11, 2018
March 12, 2018
March 12, 2018
April 16, 2010
January 12, 2017   (Final data collection date for primary outcome measure)
  • Number of Participants Who Discontinued Study-provided High Dose Fluconazole or Ampho B [ Time Frame: Measured from study entry through Week10 ]

    Discontinuation of study-provided high dose fluconazole at or by week 10 Discontinuation of study-provided ampho B at or by week 2

    Discontinuation includes discontinuing for any reason, including progression of symptoms, death, etc.

  • Categorized Quantitative Culture Results [ Time Frame: At entry, Week 2, and Week 10 ]
    Count of participants who were CM negative (had no cryptococcal growth), CM negative after switching treatment (switched from Fluconazole to Ampho B or vice versa and later became CM negative), CM positive, Died, Lost to follow-up. Note: CM positive means continued to have cryptococcal growth.
  • Change in Log10 Quantitative CSF Culture Results [ Time Frame: Entry and Week 2 ]

    Change in quantitative CSF (cerebrospinal fluid) cultures.

    Note: No further CSF specimens are drawn following a negative culture. Thus, only week 2 CSF cultures are considered in this analysis.

  • Kaplan Meier (KM) Proportion of Participant Mortality [ Time Frame: Measured from study entry through Week 24 ]
    Kaplan Meier Proportion of participants who died over study with 90% Confidence Intervals.
  • Discontinuation of fluconazole or ampho B, including precipitating and surrounding adverse events [ Time Frame: Throughout study ]
  • Qualitative and quantitative CSF culture results at entry, Week 2, and when conducted thereafter [ Time Frame: Throughout study ]
  • Survival [ Time Frame: Throughout study ]
Complete list of historical versions of study NCT00885703 on ClinicalTrials.gov Archive Site
  • Results of the Neurological Examination [ Time Frame: Measured at study entry, Week 2, and Week 10 ]
    Results from Glasgow Coma Score, which provides assessment of impairment of conscious level in response to defined stimuli. Min score of 0 and max score of 15 (no mental impairment).
  • Results of Functional Status Evaluation [ Time Frame: Measured 6 weeks before enrollment, at study entry, at Week 10, and at Week 24 ]

    Functional assessment of work status and ability. Consists of 2 measures: 1) Does participants have full time work status 2) Does participant have functional ability to work.

    The measure from 6 week before enrollment will be referred to as 'baseline'.

  • Length of Hospitalization [ Time Frame: Measured from study entry through Week 10 ]
    Duration of first hospitalization in days starting at entry in safety population.
  • Number of Hospital Admissions [ Time Frame: Measured from study entry through Week 24 ]
    Count of number of times a participant was admitted to the hospital.
  • Number of Participants With Progression of Symptoms [ Time Frame: Measured from study entry through Week 24 ]

    Progression of symptoms is defined as:

    • Died (including early deaths)
    • Discontinued Fluconazole and started ampho B
    • Had a positive cryptococcal culture at week 10
    • Microbiological Failure (i.e., relapse of CM)
    • Complication of CM (e.g., obstructive hydrocephalus or vascular complications such as venous or arterial thrombosis)
    • CM IRIS causing increased inflammation after ART exposure
    • New CNS Ol (e.g., toxoplasmosis, PML, CNS lymphoma)
    • Possibly related to CM but mechanism indeterminate
    • Other defined complication unrelated to CM
  • Number of Participants With CNS IRIS [ Time Frame: Measured from study entry through Week 24 ]
    Number of participants who were diagnosed with CNS immune reconstitution inflammatory syndrome (IRIS)
  • Number of Participants With Grade 3 and 4 Adverse Events [ Time Frame: Measured from study entry through Week 24 ]

    Occurrence of grade 3 (severe) and 4 (life-threatening) sign and symptoms events (as defined by FSTRF Appendix 29)

    Occurrence of grade 3 (severe) and 4 (life-threatening) laboratory events (as defined by FSTRF Appendix 76)

    See DAIDS AE Grading table V1.0

  • Results of the neurological examination and functional status evaluation [ Time Frame: Throughout study ]
  • Length of hospitalization and number and nature of hospital readmissions [ Time Frame: Throughout study ]
  • Recurrence/relapse of CM based on clinical presentation [ Time Frame: Throughout study ]
  • CNS immune reconstitution inflammatory syndrome (IRIS) [ Time Frame: Throughout study ]
  • Pharmacology [ Time Frame: Throughout study ]
  • Additional safety parameters including: Grade 3 and 4 adverse events; dose modifications; duration of temporary treatment interruptions; permanent discontinuation of either agent [ Time Frame: Throughout study ]
  • Antifungal drug susceptibility of cryptococcal isolates [ Time Frame: Throughout study ]
Not Provided
Not Provided
 
High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis
Cryptococcal meningitis (CM) is an infection of the membranes covering the brain and spinal cord, caused by the fungus Cryptococcus neoformans. CM most often affects people with compromised immune systems, like those with advanced HIV infection. This study explored the safety, tolerability, and therapeutic effect of a new treatment regimen with high-dose fluconazole for management of CM in HIV-infected patients.

CM is the most common central nervous system (CNS) complication of AIDS worldwide and accounts for up to a third of all deaths from AIDS in many developing countries. Current treatments for CM are lacking in both effectiveness and accessibility, particularly in limited-resources settings. Conventional therapies utilizing an amphotericin B deoxycholate (ampho B)-based regimen require maintaining intravenous access (IV) and monitoring and treating any associated complications. The price to acquire ampho B can also be prohibitive to successful treatment. Cumulatively, a treatment course with ampho B is neither cost effective nor administratively efficient, leaving patients either untreated or inadequately treated with low-dose regimens of fluconazole alone.

Fluconazole is widely available, inexpensive, can be given orally, has a demonstrated safety profile over a broad range of doses, and has proven activity against the fungus that causes CM, Cryptococcus neoformans. All of these factors make fluconazole a potential treatment option for a wide range of people. However, at its present recommended dosage, fluconazole is only expected to be successful in 34% to 42% of patients. This rate is lower than regimens combining fluconazole with other treatments including flucytosine or ampho B.

The purpose of this study was to evaluate whether high-dose fluconazole is safe and effective for the treatment of CM for up to 10 weeks. This study also collected information about treating CM with ampho B (either alone or with another drug, either flucytosine or fluconazole).

For this study, 168 HIV-infected people with CM participated for a duration of 24 weeks. This study proceeded with 2 stages and each stage consisted of up to 4 steps. Participants could take part in only one stage of the study. Stage 1 measured the maximum tolerated dose (MTD) of fluconazole in participants. Stage 2 consisted of dose validation and safety monitoring.

In Stage 1, participants were randomly assigned to receive either fluconazole only or an ampho B-based regimen (a regimen that is either ampho B alone or ampho B in combination with 5-fluorocytosine or fluconazole, according to the local standard of care).Three doses of fluconazole were tested, and the MTD was found to be 2000 mg/day. The two higher doses of fluconazole tested in Stage 1 (1600 mg/day and 2000 mg/day doses) were tested further in Stage 2 of the study.

Participants enrolled in Stage 2 were randomly assigned to receive treatment with either fluconazole only (at one of the 2 doses (1600 mg/day or 2000 mg/day) found to be safe in Stage 1) or an ampho B-based regimen.

After randomization in Step 1, participants in both Stage 1 and Stage 2 could be enrolled in up to three additional steps. In Step 2, participants who were randomly assigned to receive the ampho B-based regimen and who were intolerant to the regimen (experienced a treatment limiting toxicity [TLT]) received fluconazole (400-800mg daily). Participants who received study-provided fluconazole in Step 1 or in Step 2 could be enrolled in Step 3 if they had a negative cerebrospinal fluid (CSF) culture. Participants in Step 3 received fluconazole (400mg daily) until Week 10. At Week 10, all participants were enrolled in Step 4 and received a daily dose of fluconazole of 200mg until the end of the study (Week 24). Participants in both stages beginning treatment with ampho B received daily ampho B intravenously for up to 2 weeks.

Before entering the study, potential participants attended a screening visit where they had CSF collected via lumbar puncture. HIV testing was also conducted, along with clinical assessments, and a health and medical history questionnaire. Participants had blood collection, an electrocardiogram (ECG), and a pregnancy test (if applicable) at that visit. Once accepted into the study, participants again answered questions about their health and medication history; had a complete physical exam, blood collection, HIV testing, neurological exam, lumbar puncture, and ECG; and may have had a pregnancy test (if applicable).

Study visits occurred during Weeks 1 (at Days 1, 4, and 7), 2, 4, 6, 8, 10, and 24, and extra visits could occur for individualized reasons. Total study duration was 24 weeks. Plasma, urine, serum, and CSF samples were collected from all participants and stored for possible future use.

Note on efficacy population versus safety population: After entering the study, participants had their CM diagnosis confirmed by testing of the CSF collected via lumbar puncture. Confirmation could take up to 2 weeks after study entry. Due to the mortality rate of CM, participants received treatment before CM diagnosis confirmation. Post-entry 12 participants either reported non-confirmatory baseline results making them ineligible. An additional 2 participants were found to be ineligible for the study but died prior to being found ineligible (one had non-confirmatory baseline results, one was on a disallowed medication) All participants (n=168) are included in the safety population. Participants who were ineligible after study entry were excluded from the efficacy population (n=16). The efficacy population had 154 participants. Outcomes will specify if the efficacy population is used instead of the safety population.

Interventional
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Phase 1 was the dose escalation phase which used a sequential model. Phase 2 was the dose validation phase which used a parallel model. Analyses combine arms from Phase 1 and Phase 2, as appropriate, for validation.
Masking: None (Open Label)
Primary Purpose: Treatment
  • Cryptococcal Meningitis
  • HIV Infections
  • Drug: Fluconazole

    Step 1: [For participants randomized to Fluconazole] Induction dose of daily treatment of fluconazole given orally (adjusted according to weight).

    Step 2: [For participants randomized to Ampho B only] If participant is intolerant to Ampho B, participant transitions to fluconazole dosage of 400-800mg daily given orally.

    Step 3: If participant has a negative culture before week 10, participant transitions to consolidation therapy at dosage of 400mg daily given orally.

    Step 4: At week 10, participant transitions to maintenance therapy at dosage of 200mg daily given orally.

    Other Name: Diflucan
  • Drug: Amphotericin B
    Step 1: [For participants randomized to Ampho B] Ampho B given intravenously for approximately 2 weeks at a dosage of 0.7 to 1.0 mg/kg, dependent on a participant's weight
    Other Names:
    • Amphotericin B deoxycholate
    • Ampho B
    • Amphocin
    • Fungizone
    • AmBisome
    • Abelecet
    • Amphotec
  • Experimental: Stage 1, Fluconazole 1200mg
    Participants receive Fluconazole 1200mg induction dose in Stage 1
    Intervention: Drug: Fluconazole
  • Experimental: Stage 1, Fluconazole 1600mg
    Participants receive Fluconazole 1600mg induction dose in Stage 1
    Intervention: Drug: Fluconazole
  • Experimental: Stage 1, Fluconazole 2000mg
    Participants receive Fluconazole 2000mg induction dose in Stage 1
    Intervention: Drug: Fluconazole
  • Active Comparator: Stage 1, Ampho B
    Participants receive Amphotericin B followed by Fluconazole in Stage 1
    Interventions:
    • Drug: Fluconazole
    • Drug: Amphotericin B
  • Experimental: Stage 2, Fluconazole 1600mg
    Participants receive Fluconazole 1600mg induction dose in Stage 2
    Intervention: Drug: Fluconazole
  • Experimental: Stage 2, Fluconazole 2000mg
    Participants receive Fluconazole 2000mg induction dose in Stage 2
    Intervention: Drug: Fluconazole
  • Active Comparator: Stage 2, Ampho B
    Participants receive Amphotericin B followed by Fluconazole in Stage 2
    Interventions:
    • Drug: Fluconazole
    • Drug: Amphotericin B

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
168
192
January 12, 2017
January 12, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria - Step 1

  • CM documented either by a positive CSF cryptococcal culture, a positive CSF India ink preparation, or a positive CSF cryptococcal antigen latex agglutination test within 7 days prior to entry. More information on this criterion can be found in the protocol.
  • CSF collection for quantitative cryptococcal culture within 72 hours prior to study entry or planned to be performed at study entry
  • HIV-1 infection documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by or within 10 days after study entry by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, by HIV-1 antigen, or by plasma HIV-1 RNA viral load. More information on this criterion can be found in the protocol.
  • Ability to take oral medications. NOTE: Administration of fluconazole tablets via nasogastric tube is permitted.
  • For patients with a co-morbid complication of HIV, including opportunistic infections, reasonable certainty that the site investigator will be able to perform CSF sampling and manage expected study drug toxicities. More information on this criterion can be found in the protocol.
  • For female participants of reproductive potential (defined as girls who have reached menarche or women who have not been post-menopausal for at least 24 consecutive months [i.e., who have had menses within the preceding 24 months, or have not undergone surgical sterilization, for example, a hysterectomy, or bilateral oophorectomy or salpingotomy]) a negative serum or urine pregnancy test result must be obtained within 2 days prior to study entry
  • All participants must agree not to participate in the conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization).
  • If participating in sexual activity that could lead to pregnancy, female study participants must agree to the simultaneous use of two forms of contraception (listed in protocol) during sexual activity, and male study participants must agree to use a condom during such sexual activity. This requirement continues while the study participant is on study treatment and for 6 weeks after fluconazole has been discontinued. More information on this criterion can be found in the protocol.
  • Study participants who are not of reproductive potential (defined as women who have been post-menopausal for at least 24 consecutive months, women who have undergone surgical sterilization [e.g., hysterectomy, or bilateral oophorectomy or salpingectomy], or men who have documented azoospermia) are eligible without the requirement to use contraceptives. More information on this criterion can be found in the protocol.
  • Willingness and ability to adhere to dose schedules and mandatory procedures
  • Measured or calculated creatinine clearance of 50 mL/min or more within 3 days prior to study entry. More information on this criterion can be found in the protocol.
  • The following laboratory values within 3 days prior to study entry: aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase less than or equal to 5 times the upper limit of normal (ULN); total bilirubin less than or equal to 2.5 times ULN; absolute neutrophil count (ANC) equal to or greater than 750/mm^3; platelet count equal to or greater than 50,000/mm^3; hemoglobin equal to or greater than 7.0 g/dL
  • Ability and willingness of the participant or legal guardian/representative to give informed consent
  • Availability at the site for at least 2 weeks of its standard-of-care ampho B-based regimen

Exclusion Criteria - Step 1

  • Expected survival of 2 weeks or less, in the opinion of the site investigator and, if available, the primary care provider
  • For patients with a comorbid complication of HIV, anticipated difficulty, in the opinion of the site investigator, in judging response to study treatment as a result of the comorbid complication or the drugs used to treat it
  • Breastfeeding
  • A prior episode of CM, either as indicated by patient or as noted in patient medical records
  • Use of certain drugs within specified time periods. More information on this criterion can be found in the study protocol.
  • For candidates who are currently taking nevirapine, the inability to discontinue nevirapine and replace it with a drug that does not have fluconazole drug interactions at or by study entry in the event they are randomized to a high-dose fluconazole treatment arm. More information on this criterion can be found in the study protocol.
  • Known allergy, sensitivity to, or intolerance of fluconazole or other imidazole or triazole compounds or to ampho B or other components of the standard of care ampho B based regimen
  • History of clinically significant cardiac disease, in the opinion of the site investigator, including symptoms of ischemia, coronary artery disease, congestive heart failure, or arrhythmia
  • ECG with QTc interval greater than 450 msec within 7 days prior to study entry. More information on this criterion can be found in the study protocol.
  • History of CNS disorder (excluding mood disorders) or concurrent CNS disorder(s) that, in the opinion of the investigator, would interfere with assessment of efficacy (e.g., ability to perform CSF sampling) such as lymphoma, neurocysticercosis, or toxoplasmosis
  • Receipt of investigational drug therapy within 30 days prior to study entry without prior approval of the A5225/HiFLAC core team
  • Active drug or alcohol use, dependence, or other conditions that in the opinion of the site investigator would jeopardize the safety of a participant in the study or would render the person unable to comply with the study plan

Inclusion Criteria - Step 2

  • Randomization to an ampho B-based regimen in Step 1
  • Receipt of at least one dose of ampho B-based regimen in Step 1
  • Premature discontinuation of ampho B in response to the occurrence of any treatment-limiting toxicity, as described in Section 5 of the A5225/HiFLAC manual of operations (MOPS)

Exclusion Criteria - Step 2

  • Receipt of fluconazole monotherapy in Step 1
  • Receipt of 8.4 mg/kg or more of ampho B
  • At or beyond Day 17 in Step 1

Inclusion Criteria - Step 3

  • For participants in Step 1 who are currently receiving study-provided fluconazole and have no plans to discontinue study treatment (except as noted below), a negative CSF culture after 2 weeks incubation from a sample obtained at or before Week 6 (Days 35-49)
  • For participants in Step 1 who are currently receiving an ampho B-based regimen or alternative treatment, completion of approximately 2 weeks of treatment. More information on this criterion can be found in the study protocol.
  • For participants in Step 2 who are currently receiving study-provided fluconazole and have no plans to discontinue study treatment, negative CSF culture after 2 weeks incubation from a sample obtained at or before Week 6 (Days 35-49).

Exclusion Criteria - Step 3

  • On study treatment beyond Week 10 (Day 77) in Step 1 or Step 2
  • Currently off study treatment

Inclusion Criteria - Step 4

- On study treatment at Week 10 (Days 63-77) with no plans to discontinue study treatment

Exclusion Criteria - Step 4

- Currently off study treatment

Sexes Eligible for Study: All
16 Years and older   (Child, Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
India,   Kenya,   Peru,   South Africa,   Thailand,   Uganda,   United States,   Zimbabwe
 
 
NCT00885703
A5225 (HiFLAC)
10149 ( Registry Identifier: DAIDS-ES )
ACTG A5225
HiFLAC
A5225/HiFLAC
A5225
Not Provided
Not Provided
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Study Chair: Umesh G. Lalloo, MD, FRCP Nelson R. Mandela School of Medicine
Study Chair: Robert A. Larsen, MD USC School of Medicine
National Institute of Allergy and Infectious Diseases (NIAID)
February 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP